BURRELL INTERNATIONAL GROUP LLC for EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC )
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 19, 2019 | $10,000 | Replaced |
| 2nd Quarter - Termination (this page) | Jul 19, 2019 | $10,000 | Replaced |
| 2nd Quarter - Termination Amendment | Jul 30, 2019 | $10,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
NDAA - provisions related to biological and chemical defense Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Foreign entity interest: Emergent Biosolutions/Adapt Pharma is a U.S. domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBORAH LYNN BURRELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.